Stroke predictors for atrial fibrillation - outside the CHA₂DS₂-VA

Area of Science:

• Cardiology
• Neurology
• Clinical Risk Stratification

Background:

• Oral anticoagulation is crucial for managing atrial fibrillation and preventing stroke.
• Current risk stratification relies on the CHA2DS2-VA score, which has limitations in clinical practice.
• Improving stroke risk prediction in atrial fibrillation is essential for optimizing anticoagulation therapy.

Purpose of the Study:

• To identify clinical risk factors, biochemical markers, electrocardiogram features, and cardiac imaging findings beyond the CHA2DS2-VA score that increase stroke risk in atrial fibrillation patients.
• To explore the potential of novel risk factors to enhance the predictive accuracy of existing risk scores.
• To guide clinicians in refining anticoagulation prescribing decisions for atrial fibrillation patients.

Main Methods:

• Systematic review of literature identifying novel stroke risk factors in atrial fibrillation.
• Analysis of clinical risk factors, biochemical markers, ECG findings, and cardiac imaging.
• Evaluation of factors not included in the current CHA2DS2-VA scoring system.

Main Results:

• The CHA2DS2-VA score has modest efficacy and clinical limitations for stroke risk stratification in atrial fibrillation.
• Several novel factors (clinical, biochemical, ECG, imaging) demonstrate potential to increase stroke risk.
• These novel factors may improve the predictive ability of current risk assessment tools.

Conclusions:

• Novel risk factors can augment the CHA2DS2-VA score for more precise stroke risk stratification in atrial fibrillation.
• Integrating these factors can help identify high-risk patients initially deemed low risk.
• This approach supports personalized anticoagulation strategies in atrial fibrillation management.